JOHN D. THOMPSON JOINS TRANSGENOMIC'S BOARD OF DIRECTORS OMAHA, Neb. (

D. THOMPSON JOINS TRANSGENOMIC'S BOARD OF DIRECTORS

OMAHA, Neb. (May 15, 2014) -- Transgenomic, Inc.

(NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases

through advanced diagnostic tests and clinical and research services, today announced the appointment of John D. Thompson to its

Board of Directors. His appointment was effective May 14, 2014.

"John Thompson brings extensive experience in life sciences

business development, corporate strategy and mergers and acquisitions at top tier firms to our Board," said Rodney S. Markin,

M.D., Ph.D., Chairman of Transgenomic. "John's insights and expertise gained from his years as an influential strategist

and dealmaker at legendary life sciences firms should be extremely valuable to Transgenomic as we work to achieve a leadership

position in the rapidly growing personalized medicine arena."

Mr. Thompson commented, "We are at an important juncture

in the life sciences, as rapidly evolving technology, globalizing markets and changing customer expectations are creating large

opportunities for companies with innovative technology and the requisite business savvy. Transgenomic has unique technologies with

very large commercial potential, and I look forward to the opportunity to contribute at this exciting time for the company."

Most recently, Mr. Thompson has served as a consultant and board

member to a number of life sciences enterprises. Previously, he was Senior Vice President, Strategy and Corporate Development at

Invitrogen Corporation, where he completed over 20 transactions with an aggregate value in excess of $2 billion, in-licensed more

than 200 compounds, and charted the company's ambitious growth plans. Previously he was Senior Vice President, Strategic

and Business Development at Dexter Corporation, where he led restructuring activities involving more than a dozen acquisitions

and divestitures. Earlier he was Vice President, Financial Services and Treasurer, where he negotiated financings totaling $100

million, and refinanced multicurrency debt and credit agreements.

Mr. Thompson also worked at Dexter subsidiary, Life Technologies.

As Senior Vice President and General Manager, Americas Research Products Division, he helped achieve annual double-digit sales

and earnings growth while divesting less promising businesses. As Vice President Finance, Secretary and Treasurer, he helped focus

the business on high technology products, oversaw the merger that resulted in the formation of Life Technologies and helped ensure

the success of its IPO.

Mr. Thompson began his career in public accounting at Ernst

& Young. He received a BBS degree from Cleveland State University.

Transgenomic, Inc. is a global biotechnology company

advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic technologies, such

as its revolutionary ICE COLD-PCRTM and its unique genetic tests provided through its Patient Testing business. The

company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies

and sells equipment, reagents and other consumables for applications in molecular testing and cytogenetics. Transgenomic's

diagnostic technologies are designed to improve medical diagnoses and patient outcomes.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking

statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known

and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results,

performance or achievements expressed or implied by such statements. The known risks, uncertainties and other factors affecting

these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission.

Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from

those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements

contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release.

All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this

information, including any forward-looking statements, unless required by law.

Barbara Lindheim, 212-584-2276

Susan Kim, 212-600-1902

Donna Christian, 402-452-5416